Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Chemotherapy with TKI vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.23 [1.02, 1.49]
4 studies · 548 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.16 [0.79, 1.7]
1 study · 100 participants
Very low